We first explored whether expression of the 4 transcriptional DDR markers (Supplementary Table S1) differed according to BRCAness assessed via both genetic and epigenetic mechanisms of loss of BRCA1 or BRCA2 function (BRCA1 mutated/BRCA1 methylated/BRCA2 mutated/wild type) or HRD status (high/low as per Myriad's HRD signature) in this highly selected population of patients who developed advanced/metastatic disease. This evidence concerns the gene BRCA2 and metastatic neoplasm.